‣ Aged 18 to 80 years old

⁃ Histologically confirmed relapsed refractory FL (Module 1) and DLBCL (Module 2) after at least 2 prior lines of therapy

⁃ ECOG performance status 0 to 2

⁃ Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy

⁃ FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as \> 1.5 cm in its longest dimension), or extranodal lesion (defined as \> 1.0 cm in its longest dimension)

⁃ Adequate hematological function: ANC ≥ 1000/mm3, platelets

∙ 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening

⁃ Adequate liver function: total bilirubin \<1.5x ULN, AST/ALT ≤ 3xULN Note: Patients with documented history of Gilbert's Syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible)

⁃ Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min

• The above is a summary, other inclusion criteria details may apply.